Literature DB >> 17364883

Application of chimeric mice with humanized liver for predictive ADME.

Miki Katoh1, Tsuyoshi Yokoi.   

Abstract

Much effort to extrapolate the in vivo pharmacokinetics of drugs in human from experimental animals or in vitro studies has been made by many researchers. A urokinase-type plasminogen activator+/+/severe combined immunodeficient transgenic mouse line, in which the liver could be replaced by more than 80% with human hepatocytes, was established recently in Japan. This chimeric mouse line is remarkable because the replacement is higher than any other chimeric mouse reported previously. Since the liver is the critical organ involved in the pharmacokinetics of drugs, human liver is essential for the development of new drugs. To predict the human drug metabolism and pharmacokinetics, human hepatocytes and liver microsomes are recognized as better tools and are frequently used. Thus, chimeric mice with humanized liver would have great advantages in studies on drug metabolism and pharmacokinetics. We have evaluated chimeric mice for studies on absorption, distribution, metabolism, and excretion (ADME). In the liver of the chimeric mice, human phase I and phase II enzymes were clarified to be expressed and to have a similar drug metabolizing capacity as the donor. Human specific metabolites could be detected in the serum, suggesting that the chimeric mice might be used as a human ADME model for both in vitro and in vivo studies. For predicting human drug interactions, enzyme induction and inhibition are serious problems. By the treatment with typical inducers, human CYP1A2 and CYP3A4 expressed in the liver of the chimeric mice had induction potencies. After the treatment with quinidine, a specific inhibitor of human CYP2D6, the area under the curve (AUC) of a CYP2D6 metabolite, 4'-hydroxydebrisoquin, was significantly decreased in the chimeric mice but not in the control mice. Therefore, it was indicated that the chimeric mice could be used for assessing the drug interactions via enzyme induction and inhibition. As well as drug metabolism, the drug excretion was demonstrated to be humanized because cefmetazole was mainly excreted in urine both in the chimeric mice and human but in feces in control uPA-/-/SCID mice. In this review, basic researches on ADME in the chimeric mice with humanized liver are summarized and the application of the chimeric mice for predictive ADME is proposed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364883     DOI: 10.1080/03602530601021340

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  10 in total

Review 1.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

2.  Humanized mice with ectopic artificial liver tissues.

Authors:  Alice A Chen; David K Thomas; Luvena L Ong; Robert E Schwartz; Todd R Golub; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

3.  Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction.

Authors:  Toshihiko Nishimura; Toshiko Nishimura; Yajing Hu; Manhong Wu; Edward Pham; Hiroshi Suemizu; Menashe Elazar; Michael Liu; Ramazan Idilman; Cihan Yurdaydin; Peter Angus; Catherine Stedman; Brian Murphy; Jeffrey Glenn; Masato Nakamura; Tatsuji Nomura; Yuan Chen; Ming Zheng; William L Fitch; Gary Peltz
Journal:  J Pharmacol Exp Ther       Date:  2012-11-08       Impact factor: 4.030

Review 4.  Humanized mice for modeling human infectious disease: challenges, progress, and outlook.

Authors:  Nicolas Legrand; Alexander Ploss; Rudi Balling; Pablo D Becker; Chiara Borsotti; Nicolas Brezillon; Jennifer Debarry; Ype de Jong; Hongkui Deng; James P Di Santo; Stephanie Eisenbarth; Elizabeth Eynon; Richard A Flavell; Carlos A Guzman; Nicholas D Huntington; Dina Kremsdorf; Michael P Manns; Markus G Manz; Jean-Jacques Mention; Michael Ott; Chozhavendan Rathinam; Charles M Rice; Anthony Rongvaux; Sean Stevens; Hergen Spits; Hélène Strick-Marchand; Hitoshi Takizawa; Anja U van Lent; Chengyan Wang; Kees Weijer; Tim Willinger; Patrick Ziegler
Journal:  Cell Host Microbe       Date:  2009-07-23       Impact factor: 21.023

5.  Can 'humanized' mice improve drug development in the 21st century?

Authors:  Gary Peltz
Journal:  Trends Pharmacol Sci       Date:  2013-04-19       Impact factor: 14.819

Review 6.  LC-MS-based metabolomics in drug metabolism.

Authors:  Chi Chen; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

7.  Lack of human relevance for procymidone's developmental toxicity attributable to species difference in its kinetics and metabolism.

Authors:  Yoshitaka Tomigahara; Hirokazu Tarui; Masayoshi Matsui; Motohiro Kurosawa; Satoshi Kawamura; Naohiko Isobe
Journal:  J Pestic Sci       Date:  2018-05-20       Impact factor: 1.519

Review 8.  Cell and tissue engineering for liver disease.

Authors:  Sangeeta N Bhatia; Gregory H Underhill; Kenneth S Zaret; Ira J Fox
Journal:  Sci Transl Med       Date:  2014-07-16       Impact factor: 17.956

9.  Intravenous Delivery of piggyBac Transposons as a Useful Tool for Liver-Specific Gene-Switching.

Authors:  Shingo Nakamura; Masayuki Ishihara; Satoshi Watanabe; Naoko Ando; Masato Ohtsuka; Masahiro Sato
Journal:  Int J Mol Sci       Date:  2018-11-02       Impact factor: 5.923

10.  The nude mouse as model for liver deficiency study and treatment and xenotransplantation.

Authors:  Isabelle Vidal; Lysiane Richert
Journal:  Int J Hepatol       Date:  2012-10-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.